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INTENTIONAL INDUCTION OF MIXED HEMATOPOIETIC CHIMERISM AS
PLATFORM FOR CELLULAR THERAPY AFTER HLA-MATCHED ALLOGE-
NEIC STEM CELL TRANSPLANTATION IN CHILDHOOD LEUKEMIA PA-
TIENTS
Perez, A.1, Gonzalez, M.1, Ramirez, M.1, Sevilla, J.1, Diaz, M.A.1
1Hospital “Nin˜o Jesus”, Madrid, Spain.
To maximize graft-versus-leukemia (GvL) effect while minimiz-
ing or avoiding graft-versus-host disease (GvHD) we designed a
prospective study of allogeneic PBSC transplantation aimed to
achieve a mixed chimerism (MC) status. In order to ensure this
objective we combined the use of reduced-intensity conditioning
and graft manipulation by means of CD34 selection. To improve
immunological reconstitution early “low dose” (0.5  105/Kg
CD3 cells) DLI was scheduled once a month for six months. The
PBSC CD34 selection was performed by CliniMACS device.
Between June 2004 and June 2006, twenty two consecutive patients
(8 females and 14 males) aged between 1-16 years (median 6 years)
diagnosed of AML 9, ALL 13 were conditioned with ﬂudarabine
30 mg/m2/day x 5 days plus melphalan 140 mg/m2/day x 1 day
(n19) or plus busulphan 3.2 mg/kg/day x 2 days (n2). Status at
transplantation was 1st CR 14, 2nd CR 7 and 3th CR 1. GvHD
prophylaxis consisted of CsA  short Mtx. Patients were grafted
with a median number of 6  106/Kg CD34 cells (range: 2-31 
106/Kg) and 1.1  104 CD3 cells (range: 0.2-3.9  104/Kg). All
patients engrafted and MC was detected in all. Median time to
neutrophil and platelet engraftment was 13 days (range: 9-16 days)
and 13 days (range: 8-24 days), respectively. A total of 65 DLI were
performed. One patient had acute GvHD grade I after 2nd DLI
that resolved with topical steroid treatment and another one de-
veloped graft hypoplasia after ﬁrst DLI resolved after G-CSF
treatment. One patient died due to engraftment syndrome. No
patients developed GvHD  grade II. The Kaplan-Meier proba-
bility of relapse was 229%. With a median follow-up of 15
months (range: 3-24 months) the probability of disease-free sur-
vival was 789%. The secondary graft failure probability was
205%. Risk factors for secondary graft failure were sex-mismatch
(female recipient-male donor) and transplantation from unrelated
donors. The main cause of death was relapsing disease. No severe
viral and fungal infections were observed. These preliminary re-
sults suggest that the intentional induction of MC avoids serious
GvHD but it is not associated with an increase risk of relapsing
disease. However, secondary graft failure is an emerging problem
especially in the unrelated transplantation setting.
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CHRONIC GVHD DECREASES ANTI-CMV IMMUNE RESPONSES IN ALLO-
GENEIC BMT: DEFECT IN T-CELL HOMING
Hossain, M.S.1, Roback, J.D.2, Pollack, B.P.3, Jaye, D.L.2,
Waller, E.K.1 1Department of Hematology and Oncology, Emory Uni-
versity, Atlanta, GA; 2Department of Pathology and Laboratory Medi-
cine, Emory University, Atlanta, GA; 3Department of Dermatology and
Pathology, Emory University, Atlanta, GA.
Backgound: The major complications of allogeneic bone marrow
transplantation are relapse, acute and chronic Graft-vs-Host Dis-
ease (aGvHD; cGvHD) and opportunistic infections, especially
cytomegalovirus (CMV). In this study, we investigated the effect of
cGvHD on susceptibility to murine CMV infection following
allogeneic BMT, focusing on the contribution of cGvHD to func-
tional immunodeﬁciency.
Method: We used a parent to F1 model of allogeneic BMT to
test the hypothesis that cGvHD leads to impaired anti-viral im-
munity. Irradiated CB6F1 recipients of 3106 untreated donor
splenocytes developed non-lethal cGvHD compared to control
mice without GvHD that had received TCD bone marrow alone
or BM plus amotosalen (a water soluble synthetic S-59 psoralen
compound) -treated splenocytes10106. Mice were challenged
with a non-lethal dose of murine CMV 100 days post transplant.
Flow cytometry was used to quantitate T cells isolated from the
recipient organs. Liver viral load was determined by counting PFU
in tissue homogenates plated onto 3T3 conﬂuent monolayers.
Assessment of cGvHD was done by monitoring weight loss and
scored through histological analysis of tissue sections.
Results: Recipients with cGvHD had more weight loss and
higher viral loads in the spleen and liver. Murine CMV infection
led to 130- and 30 -fold expansion of donor spleen-derived T-cells
in the blood of transplant recipients with and without chronic
GvHD, respectively, as well as marked expansion of CMV-pep-
tide-speciﬁc-tetramer CD8 T-cells. Mice with chronic GvHD
had lymphopenia in secondary lymphoid organs and severe depres-
sion of the numbers of antigen-speciﬁc anti-viral T-cells in the
spleen and liver compared to control mice.
Conclusion: Functional immunodeﬁciency in mice with cGvHD
and MCMV infection are consistent with the clinical reports that
document an increased incidence of opportunistic viral infections
in patients with cGvHD. Expansion of donor T cells in blood
occurred against viral infection but these T-cells failed to mount
effective anti-viral immune responses in the spleen and liver. In
contrast transplant recipients of amotosalen-treated splenocytes
successfully developed brisk and effective anti-viral immune re-
sponses. These ﬁndings provide an opportunity to design a novel
approaches for the treatment of cancer patients undergoing allo-
geneic BMT that may reduce the incidence of cGvHD, organ
speciﬁc immunodeﬁciency and opportunistic infections.
Table 1. T cells in the blood and liver of recipients with cGvHD, and
no GvHD after day 10 MCMV infection1.
Blood Liver
cGvHD
No GVHD
cGvHD cGvHD
No GVHD
cGvHD
T cell number2
Donor spleen 130 31.0 3.8 2.49
Donor BM 7.1 11.1 3.2
Host 15.0 6.8 2.7 1.8
Absolute numbers of
MCMV specific
tetramer CD8
T cells per tissue3
Donor spleen 38.6  33.1 9.3  5.5 50.1  38.6 178  124.9*
Donor BM 13.6  8.5* 32.1  9.2* 65.2  45.8 226.3  99.2*
Host 6.2  6.2 11.3  4.5* 17.9  6.1 14.2  11.1
1Recipients of untreated splenocytes (cGvHD) and amotosalen-
treated (no GvHD) were bled on 133 days post transplant (day
0), and bled on day 10 after 5104 PFU MCMV i.p. infection.
Liver lymphocytes were isolated on day 0 after MCMV infec-
tion (day100 post transplant) and day 10 after post infection.
2The fold-expansion data were calculated by dividing number of
T-cells per ml of blood and per liver on day 10 postinfection
with the baseline number of T-cells present on day 0 of infec-
tion.
3The absolute number of MCMV peptide speciﬁc tetramer
CD8 T cells (x103)T cells per mL of blood and per liver were
determined by FACS analysis on day 10 after MCMV infec-
tion. *p0.05(Student t-test) compared with the cGvHD. 4 to
5 mice were used per group.
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HIGHER-ORDER CYTOKINE FLOW CYTOMETRY REVEALS DISTINCT
FUNCTIONAL SIGNATURES OF MATURATION SUBSETS OF CD4 AND
CD8 T CELLS
Kim, T.K.1, St. John, L.S.1, Wieder, E.D.1, Molldrem, J.J.1,
Komanduri, K.V.1 1Dept. of Stem Cell Transplantation & Cellular
Therapy, MD Anderson Cancer Center, Houston, TX; University of
Houston, Houston, TX; University of Houston, Houston, TX; Fleury-
Diagnostic Medical Center, Sao Paolo, TX.
Our clinical studies have suggested that impaired immune recov-
ery after SCT is associated with greater proportions of circulating
memory and late memory cells, as deﬁned by phenotyping. To
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characterize the relationship between immunophenotypic markers
of T cell maturation and functional attributes of T cells, we
optimized an 8-color, 10-parameter cytokine ﬂow cytometry
(CFC) approach and examined PBMC in 3 healthy donors. PBMC
were exposed to stimuli that both bypass and signal through the T
cell receptor (PMA/Ionomycin&em;P:I and staph enterotoxin
B&em;SEB, respectively) and stained with CD45RA and CD27 to
demarcate naı¨ve (N, CD45RACD27), memory (M, CD45RA-
CD27-) and late-memory (LM, CD45RACD27-) CD4 and
CD8 T cells. We assessed the production of effector cytokines
(IL-2, IFN, TNF
 and MIP1) within the three maturation
subsets. Following PMA and SEB stimulation, all maturation sub-
sets (N, M and LM) of CD4 and CD8 T cells produced IFN.
TNF
 production was similarly distributed after P:I stimulation.
However, after SEB stimulation, LM CD4 and CD8 cells
produced only 2.5% and 8.5% of total TNF
, respectively. Pro-
duction of IL-2 and MIP1- was much more skewed, with LM
cells contributing little to total IL-2 production after stimulation
with P:I (0.2% of total, CD4; 0%, CD8) or SEB (CD4, 2.1%;
CD8, 2.8%). While LM cells produced little or no IL-2, they
produced the bulk of MIP1- following stimulation with P:I
(96.5%, CD4; 84.8%, CD8) or SEB (97.5%, CD4; 70.7%, CD8).
Co-production of IL-2 and IFN in T cells has recently been
postulated to be important for protective immunity. Importantly,
no IL-2IFN cells were seen in the LM compartment follow-
ing P:I stimulation (CD4 Distribution: 8.9% N, 91.1% M, 0%
LM; CD8: 15.7% N, 84.3% M, 0% LM). Results following SEB
stimulation were similar (CD4: 3.3% N, 94.9% M, 1.8% LM;
CD8: 12.2% N, 87.8% M, 0% LM). Overall, these results suggest
that: 1) T cell maturation stage does correlate strongly with func-
tional capacity; 2) Nearly all IL-2 production occurs in N and M
cells; 3) LM cells produce little or no IL-2; but most of total
MIP-1; 4) IL-2/IFN co-production is absent in LM cells, per-
haps suggesting why late-stage skewing after SCT is associated
with functional T cell impairment; and 5) Maturation stage appears
to be more closely associated with functional status than CD4 or
CD8 lineage. These results may have important implications for
clinical studies of post-SCT immune recovery and GVHD.
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CLINICAL EFFICACY OF LONG-TERM LOW DOSE ACYCLOVIR FOR VZV
INFECTION PROPHYLAXIS AFTER ALLOGENEIC PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION
Kim, D.H.13, Messner, H.A.1, Gupta, V.1, Kuruvilla, J.1, Chae, Y.S.2,
Sohn, S.K.2, Lipton, J.H.1 1Princess Margaret Hospital, Toronto, ON,
Canada; 2Kyungpook National University Hospital, Daegu, Korea;
3Samsung Medical Center, Seoul, Korea.
The current study evaluated the clinical efﬁcacy of long-term low
dose acyclovir (ACV) prophylaxis for varicella-zoster virus (VZV)
after allogeneic peripheral blood stem cell transplantation (PB-
SCT). The clinical data of transplant records since 2000 has been
retrospectively retrieved from 2 transplant centers. Princess Mar-
garet Hospital (PMH) group used ACV 400mg/day po till day 28,
whlie Kyungpook National University Hospital (KNUH) group
adopted ACV 800-1200mg/day po till at least 6-9 months. PMH
group (n193) was prone to more lymphoproliferative disorder,
and more TBI-based regimen, while KNUH group (n79) was
prone to more mismatched PBSCT, and high risk acute leukemia
patients. Out of 193 pts in PMH group, 26 patients (13.5%)
received long-term ACV prophylaxis, while 73 patients (92.4%) in
KNUH group received. Overall survival (OS) showed a trend of
favorable survival toward PMH group (p0.227), while no differ-
ence of OS between 2 groups was noted conﬁned to HLA-identical
sibling PBSCT (p0.793). In PMH group, 42 cases (22%) devel-
oped VZV infection presented as localized (n36) or disseminated
involvement (n6), while 6 cases (8%) of VZV infection was noted
in KNUH group presenting as localized involvement (n6;
p0.005). With median 26.5 months of follow-up among survi-
vors, the incidences of VZV infection at 1 and 2 years were
19.23.3 and 27.04.1% in PMH, and 3.42.4 and 8.64.3% in
KNUH group, respectively (p0.002). When conﬁned to HLA-
identical sibling transplants, the incidence of VZV infection at 2
years was 26.44.3% at PMH, and 8.84.4% at KNUH
(p0.004). Taking into account for other potential risk factors for
VZV infection in multivariate analysis, the use of long-term ACV
as a time-dependent covariate was identiﬁed as the only indepen-
dent risk factor for VZV infection after allogeneic PBSCT
(p0.001, HR 0.130, 95% C.I. [0.0400.425]). Long-term use of
ACV seemed to be protective from VZV infection after allogeneic
PBSCT. Further prospective study on the role of low dose ACV is
strongly warranted in allogeneic PBSCT setting.
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EARLY RECOVERY OF HOST T CELLS PREDICTS PRIMARY GRAFT RE-
JECTION FOLLOWING NON-MYELOABLATIVE CONDITIONING ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Koyama, M.1, Hashimoto, D.1, Kamezaki, K.1, Numata, A.1,
Sakoda, Y.1, Aoyama, K.1, Takenaka, K.1, Miyamoto, T.1, Harada, N.1,
Nagafuji, K.1, Akashi, K.1, Tanimoto, M.2, Harada, M.1, Teshima, T.1
1Kyushu University Graduate School of Medical Science, Fukuoka, Ja-
pan; 2Okayama University Graduate School of Medicine and Dentistry,
Okayama, Japan.
The incidence of graft rejection is increasing in association
with an increased use of non-myeloablative conditioning regi-
men, alternative donors, and cord blood transplantation. We
investigated a role of host T cells in graft rejection following
non-myeloablative conditioning bone marrow transplantation
(BMT) in an MHC mismatched B6D2F1 (H-2b/d) into B6
(H-2b) mouse model of BMT, where host T cells can be acti-
vated to kill donor cells. BMT following 6 Gy, 7Gy, and 10Gy
total body irradiation (TBI) resulted in a primary graft rejection,
secondary graft rejection, and engraftment of donor cells, re-
spectively. Interestingly, expansion of host T cells is observed in
the bone marrow and spleen 2 weeks after BMT, followed by a
brisk increase in number of host T cells in peripheral blood one
week later. CD8 T cells isolated from bone marrow produced
interferon-gamma and lysed donor cells. We then examined
whether donor-derived dendritic cells (DCs) play a role in this
rejection, using transgenic mice carrying diphtheria toxin re-
ceptor (DTR) under the control of the CD11c promoter, which
allows selective ablation of CD11c DCs by injection of diph-
theria toxin (DTx), as donors. In the recipients conditioned with
6Gy TBI, depletion of donor-derived DCs with DTx injection
reduced the host T cell-expansion and leads to transient mixed
chimerism in contrast to primary graft rejection in controls. We
then tested whether such an early recovery of host T cells could
be predictive of the graft rejection in 7 adult recipients of
non-myeloablative cord blood transplantation. Three week
post-transplant, an overshoot of host T cells was observed in 2
patients who experienced rejection, but in none of 5 patients
with engraftment. These results suggest that residual host T
cells are associated with graft rejection and an early recovery of
host T cells may be predictive of graft rejection after non-
myloablative allogeneic hematopoietic stem cell transplantation.
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CLINICAL EFFICACY OF CRYOPRESERVED DONOR LYMPHOCYTES FOR
INFUSION (DLI)
Lane, T.A.1, Medina, B.1, Bashey, A.1, Holman, P.1, Carrier, E.1,
Castro, J.1, Ball, E.D.1 1Univ. of CA, San Diego, School of Medicine, La
Jolla, CA.
DLI are frequently employed after nonmyeloablative (mini)
allogeneic marrow transplant (allo-BMT) to enhance chimer-
ism. To ensure the ready availability of cells for DLI we cryo-
preserved CD3 cells from mobilized allo-BMT donors. We
report here the safety and efﬁcacy of infusing cryopreserved
CD3 T cells for DLI (c-DLI) from G-CSF mobilized allo-
PBSC donors and the overall clinical utility of c-DLI. Methods:
Graded doses of CD3 donor T cells from allo-PBSC (2 bags
of 10  106 & 2 of 50  106/kg pt wgt) were cryopreserved in
10% DMSO using a controlled rate freezer and stored in vapor-
phase liquid nitrogen until use. We reviewed patients (pts) who
received allo-BMT for hematologic malignancy from 1/03 to
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